Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients

[1]  R. Hills,et al.  Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[3]  W. Wood,et al.  Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. , 2017, Blood.

[4]  Bas J. Wouters,et al.  Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. , 2017, The Journal of molecular diagnostics : JMD.

[5]  G. Behre,et al.  Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning , 2017, Bone Marrow Transplantation.

[6]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[7]  J. Cayuela,et al.  Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Karas,et al.  Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission. , 2016, Anticancer research.

[9]  E. Estey,et al.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Krämer,et al.  Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia , 2016, Blood Cancer Journal.

[11]  E. Estey,et al.  Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia , 2016, Leukemia.

[12]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[13]  F. Gao,et al.  Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  B. Wood,et al.  Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation , 2013, Leukemia.

[15]  D. Grimwade,et al.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.

[16]  E. Hoster,et al.  Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse , 2014, Haematologica.

[17]  Uku. Innere Medizin.  Clonal evolution in relapsed NPM1 mutated acute myeloid leukemia , 2014 .

[18]  E. Estey,et al.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.

[19]  O. Landt,et al.  The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.

[20]  N. Kröger,et al.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT , 2013, Bone Marrow Transplantation.

[21]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[22]  Yan-rong Liu,et al.  Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. , 2012, Blood.

[23]  E. Estey,et al.  Continuing medical education activity in American Journal of Hematology , 2011 .

[24]  A. Kiani,et al.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial , 2011, Leukemia.

[25]  R. Hills,et al.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.

[26]  K. Döhner,et al.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[29]  T. Haferlach,et al.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.

[30]  M. Baccarani,et al.  NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia , 2007, Haematologica.

[31]  M. Yao,et al.  Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations , 2007, Leukemia.

[32]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[33]  M. Maris,et al.  Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors , 2006 .

[34]  W. Hiddemann,et al.  Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.

[35]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[36]  J. Sierra,et al.  No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission , 2000, British journal of haematology.

[37]  R. Storb,et al.  Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. , 1982, International journal of radiation oncology, biology, physics.